Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

116 results about "Catabolism" patented technology

Catabolism (/kəˈtæbəlɪsm/) is the set of metabolic pathways that breaks down molecules into smaller units that are either oxidized to release energy or used in other anabolic reactions. Catabolism breaks down large molecules (such as polysaccharides, lipids, nucleic acids and proteins) into smaller units (such as monosaccharides, fatty acids, nucleotides, and amino acids, respectively). Catabolism is the breaking-down aspect of metabolism, whereas anabolism is the building-up aspect.

Enhancing hydrogen and carbon dioxide use in acetogenic monocultures and cocultures

PCT designated stageWO2025178825A2BacteriaMicroorganism based processesBiotechnologyUptake hydrogenase
A method for enhancing hydrogen uptake by cells of an acetogenic bacterium in a culture is provided. The method comprises incubating the cells in a liquid medium supplemented with an external gas mixture, wherein the external gas mixture comprises H2 and CO2; overexpressing an uptake hydrogenase and an associated electron transfer protein in the cells; increasing uptake of the H2 by the cells; and enhancing uptake of the CO2 by the cells. The culture may be a coculture with additional cells of a non-acetogenic bacterium, which produces natively H2 from catabolism of an organic molecule.
Owner:PAPOUTSAKIS ELEFTHERIOS +2

A genetically engineered bacterium for synthesizing N-acetylglucosamine, its preparation method and application

The present invention provides a genetically engineered bacterium for synthesizing N-acetylglucosamine, a preparation method thereof, and an application thereof. The genetically engineered bacterium uses Escherichia coli as an initial bacterium, and related genes for the catabolism of N-acetylglucosamine are knocked out on the genome of the initial bacterium, and related genes for the metabolic synthesis of N-acetylglucosamine are overexpressed, so as to improve the production level of N-acetylglucosamine. Among them, the related genes for the catabolism of N-acetylglucosamine include any one or a combination of at least two of nagB, nagA, manX, nagE, nagK, or ptsG, and the related genes for the metabolic synthesis of N-acetylglucosamine include any one or a combination of at least two of glmS, gna1, glnA, yqaB, icaC, galP, or glk.
Owner:BY HEALTH CO LTD

Preparation of plantain herb polysaccharide and application of plantain herb polysaccharide in preparation of medicine for preventing and treating fatty liver hemorrhagic syndrome of laying hens

The invention discloses preparation of plantain herb polysaccharide and application of plantain herb polysaccharide in preparation of medicine for preventing and treating fatty liver hemorrhagic syndrome of laying hens, and belongs to the technical field of biological medicine. The invention also provides application of the plantain herb polysaccharide in preparation of a feed additive for regulating and / or treating fatty liver of laying hens. According to the application disclosed by the invention, through in-vivo and in-vitro experimental modeling and detection of related indexes, the prevention and treatment effects of plantain herb polysaccharides with different doses on laying hen fatty liver caused by high-energy low-protein daily ration are comprehensively discussed, and hepatic lipid deposition is reduced by regulating hepatic lipid synthesis and oxidative catabolism as well as ferroptosis related signal channels; therefore, the laying hen fatty liver hemorrhagic syndrome induced by high-energy low-protein daily ration is effectively prevented and treated. The invention also researches the prevention and treatment effects of the plantain herb polysaccharide on the egg yield of laying hens and the fatty liver, and finds that the plantain herb polysaccharide can improve the egg yield of the laying hens and improve the production performance.
Owner:JIANGXI AGRICULTURAL UNIVERSITY

Application of Aldometanib in preparation of medicine for preventing and treating immune-related adverse reactions and diseases

The invention provides an application of a compound Aldometanib in preparation of a medicine for preventing and treating immune-related adverse reactions and diseases. Based on the first discovered prevention and treatment effects of Aldometanib on fatal immune hepatitis, immune myocarditis, pneumonia and enteritis, the invention specifically discloses application of Aldometanib in preparation of drugs for prevention and treatment of immune-related adverse reactions and diseases, and the main mechanism is that Aldometanib activates immune cells AMPK, enhances catabolism of immune cells, promotes immune cell apoptosis, promotes immune cell apoptosis, and improves immune cell apoptosis. The anabolism of the immune cells is inhibited, so that the expression of effector factors of the immune cells is controlled, and inflammatory factor storm is inhibited. Aldometanib has the effects of preventing the occurrence of immune-related adverse reactions and diseases, and inhibiting the attack levels of the immune-related adverse reactions and diseases, so that non-lethal and lethal injuries caused by an immune system to body organs are reduced.
Owner:FUJIAN CANCER HOSPITAL (FUJIAN CANCER INST FUJIAN CANCER PREVENTION & CONTROL CENT)

Weight-reducing and blood-sugar-reducing meal replacement powder for increasing satiety and preparation method thereof

The invention discloses weight-reducing and blood-sugar-reducing meal replacement powder for increasing satiety and a preparation method thereof, and belongs to the technical field of meal replacement powder. Comprising resistant starch, bio-enzyme modified whey protein concentrate, bio-enzyme modified soybean protein isolate, bio-enzyme modified white kidney bean hydrolyzed protein, oat fiber powder, nano emulsion milk powder, mogroside, chitosan, inulin, konjac powder, pumpkin seed powder, a cactus extract, a griffonia simplicifolia seed extract and a Chinese waxgourd peel extract. Through the synergistic effect of multiple components and multiple processes, the obvious effects of satiety, weight loss and blood sugar reduction are achieved. 5-hydroxytryptophan in the griffonia seed extract can regulate satiety center and delay hunger sensation; dietary fibers such as the resistant starch and the inulin absorb water and swell in intestinal tracts to form high-viscosity gel, so that the satiety is further enhanced, and the eating frequency and the eating amount are reduced. A low-calorie and high-protein formula is combined with components such as tartronic acid in the Chinese waxgourd peel extract and the cactus extract, so that fat catabolism is accelerated, and fat synthesis is inhibited.
Owner:JINAN SPURI MEDICAL EQUIPMENT CO LTD

Mononuclear cell for treating sepsis cardiomyopathy and application thereof

The invention provides a mononuclear cell for treating sepsis cardiomyopathy, and also relates to application of the mononuclear cell in preparation of drugs for improving sepsis and sepsis cardiomyopathy. The mononuclear cell provided by the invention can have a better targeted enrichment characteristic, so that the effective rate of treatment is improved, and meanwhile, toxic and side effects caused by non-specific distribution of drugs are reduced. Besides, the mononuclear cells are derived from the body of a healthy body, so that the mononuclear cells are more stable in metabolism, higher in absorption efficiency and more excellent in enrichment effect when acting on the body, and the technical problems that in-vivo half-life period of drugs is short and catabolism is easy in the prior art are solved.
Owner:ZHEJIANG UNIV

Application of YTHDF1 in regulation and control of tryptophan metabolism to promote formation of hepatocellular carcinoma immunosuppression microenvironment

The invention discloses a key effect and a targeted intervention strategy of YTHDF1 in regulation and control of a hepatocellular carcinoma immunosuppression microenvironment. In the tumor-associated fibroblasts, YTHDF1 enhances the translation efficiency of OTUD5 mRNA through an m6A dependency mechanism, an up-regulated deubiquitination enzyme OTUD5 is directly combined with a tryptophan metabolic rate-limiting enzyme IDO1, ubiquitination degradation of the tryptophan metabolic rate-limiting enzyme IDO1 is inhibited, tryptophan is further driven to catabolism to generate kynurenine, regulatory T cell differentiation is promoted, and an immunosuppression microenvironment is formed. Spatial transcriptomics shows that YTHDF1 + CAFs and Tregs are significantly co-localized in tumor tissues and have metabolic interaction. Based on artificial intelligence virtual screening, it is found that a natural compound hesperidin can be specifically combined with a YTH structural domain of YTHDF1, an OTUD5-IDO1 signal axis mediated by the natural compound hesperidin is blocked, and the KYN level is remarkably reduced. Animal experiments prove that the tumor inhibition rate of combined treatment of hesperidin and anti-PD-1 is increased by 40% or above compared with that of a single drug group, and synergistic interaction is achieved by inhibiting Tregs infiltration and enhancing the activity of cytotoxic T lymphocytes.
Owner:JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY)

New lactic acid bacteria

The present invention relates to lactose-positive, sucrose-negative, Streptococcus thermophilus strains. The strains are carrying one or more mutation in one or more gene of the sucrose regulon and optionally one or more further mutation affecting the glucose porter, such as affecting glcU and / or its expression. The strains of the present invention may further carry mutations in genes encoding a protein of the mannose-glucose-specific PTS and a glucokinase, a protein of the mannose-glucose-specific PTS and the catabolite control protein A (CcpA), and / or a protein of the mannose-glucose-specific PTS, a glucokinase and CcpA. The inventive strains may, when fermenting milk do this without the need or with a need for adding a reduced amount of sucrose, optionally providing a low-lactose fermented milk and / or a fermented milk not undergoing post-acidification when stored at fermentation temperature. The invention also concerns a composition comprising at least one, lactose-positive, sucrose-negative, Streptococcus thermophilus strain of the invention, and the use of this strain or composition to manufacture a fermented dairy product.
Owner:INT N&H DENMARK APS

A motile injectable cell that accelerates musculoskeletal connective tissue repair

PCT designated stage expiredWO2025155768A1AntipyreticGenetically modified cellsTissue repairCXCR4
Embodiments of the present invention disclose a genetically modified cell that accelerates tissue repair by overexpressing CXCR4. This motile cell can be administered to subjects in need, enhancing tissue regeneration compared to unmodified cells. The cell may include various progenitor cell lines and demonstrates low NF-Kb pathway activity, which suppresses catabolic activity and promotes anabolism in inflammatory environments. The invention also encompasses methods of treatment using these cells, compositions containing them, and kits for their delivery.
Owner:RHODE ISLAND HOSPITAL

Methods and compositions for particulated and reconstituted tissues

Particulated and reconstituted tissues comprising small, densely packed tissue microparticles encapsulated in a tissue specific promoting gel packed at a percolation threshold that can be transplanted into damaged tissue thereby facilitating regeneration following trauma to the tissue. The engineered microparticle construct for tissue replacement and repair, as taught herein, provides numerous benefits including (1) encouraging a regenerative response in damaged tissue regions, (2) mimicking the structural support of native tissue, (3) establishing an environment that promotes attachment, migration, and differentiation of infiltrating stem cells, and (4) providing a source of growth factors and other anti-catabolic growth factors and cytokines. Tissue specific microparticles packed together at, or past, their percolation threshold will provide the necessary mechanical environment and to best recapitulate and integrate with native tissue. The packing of microparticles, derived from the ECM of native tissue to a concentration past the percolation point will yield both the necessary biochemical and biomechanical properties necessary for reconstituting a specific tissue.
Owner:THE REGENTS OF THE UNIVERSITY OF COLORADO

Application of thiamine in preparation of product for treating subclinical ketosis of dairy cow

The invention discloses application of thiamine in preparation of a product for treating subclinical ketosis of dairy cows, and belongs to the field of biological medicines. Tests prove that compared with dairy cows suffering from subclinical ketosis (SCK), by adding thiamine, the content of beta-hydroxybutyric acid (BHBA), the number of bacteria in milk and the number of somatic cells can be remarkably reduced, and the milk yield, the milk fat content, the acetic acid content and the A / P ratio are remarkably increased; the microbial diversity of rumen and excrement of the dairy cow can be adjusted; a metabonomics result shows that metabolite up-regulated after the thiamine is added mainly focuses on pyruvic acid metabolism, glycolysis or gluconeogenesis, tyrosine metabolism, glycerophospholipid metabolism and biosynthetic pathways of phenylalanine, tyrosine and tryptophan. The conclusion is that when thiamine is added into the SCK dairy cow, synthesis and catabolism of BHBA of an organism can be effectively regulated and controlled by adjusting the content of succinyl-coenzyme A, then subclinical ketosis is relieved, rumen fermentation is promoted, and therefore the milk yield and the milk quality are improved.
Owner:JIANGXI AGRICULTURAL UNIVERSITY

Preparation of plantain polysaccharide and its application in the preparation of drugs for preventing and treating fatty liver hemorrhagic syndrome in laying hens

The present invention discloses the preparation of plantain polysaccharide and its application in the preparation of drugs for preventing and treating fatty liver and hemorrhagic syndrome in laying hens, belonging to the field of biomedicine technology. The present invention also provides the application of plantain polysaccharide in the preparation of feed additives for regulating and / or treating fatty liver in laying hens. The present invention comprehensively explores the preventive and therapeutic effects of different doses of plantain polysaccharide on fatty liver in laying hens induced by high-energy and low-protein diets through in vitro and in vivo experimental modeling and detection of relevant indicators, and reduces liver fat deposition by regulating liver fat synthesis and oxidative catabolism and ferroptosis-related signaling pathways, thereby effectively preventing and treating fatty liver and hemorrhagic syndrome in laying hens induced by high-energy and low-protein diets. The present invention also studies the preventive and therapeutic effects of plantain polysaccharide on egg production and fatty liver in laying hens, and concludes that plantain polysaccharide can increase egg production in laying hens and improve production performance.
Owner:JIANGXI AGRICULTURAL UNIVERSITY

Methods for stabilizing production of acetyl-coenzyme a derived compounds

The present disclosure relates to the use of a switch for the production of heterologous non-catabolic compounds in microbial host cells. In one aspect, provided herein are genetically modified microorganisms that produce non-catabolic compounds more stably when serially cultured under aerobic conditions followed by microaerobic conditions, and methods of producing non-catabolic compounds by culturing the genetically modified microbes under such culture conditions. In another aspect, provided herein are genetically modified microorganisms that produce non-catabolic compounds more stably when serially cultured in the presence of maltose followed by the reduction or absence of maltose, and methods of producing non-catabolic compounds by culturing the genetically modified microbes under such culture conditions.
Owner:TOTAL MARKETING SERVICES SA

kit

ActiveCN116370693BActs as a filling and firming agentContinuously fills and tightensSuture equipmentsBio-packagingHuman bodyFibroblast
The present disclosure relates to a kit. The kit of the present disclosure comprises: a kit body comprising a needle tube and a needle, the first end of the needle being mounted to the needle tube; and a catabolic filling thread comprising a first segment and a second segment connected to each other, at least a part of the first segment being located inside the needle, and at least a part of the second segment being located outside the needle, wherein the catabolic filling thread is a thread made of poly-L-lactic acid. The kit of the present disclosure comprises a catabolic filling thread which can be composed of poly-L-lactic acid, is absorbable, has no residue, and is metabolized into lactic acid in the human body. Such a configuration makes the catabolic filling thread itself not only play a role in filling and tightening when filling surgery is performed using the catabolic filling thread of the present disclosure, but also the lactic acid after its metabolism can still stimulate fibroblasts in the skin and subcutaneous tissue to reconstruct the collagen framework in the human body by using fibroblasts.
Owner:KANG SIRONGYI (BEIJING) TECHNOLOGY DEVELOPMENT CO LTD

Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds

PendingUS20260125432A1FungiFusion with degradation motifPost translationalGene Modification
The present disclosure relates to the use of a maltose dependent degron to control stability of a protein of interest fused thereto at the post-translational level. The present disclosure also relates to the use of a maltose dependent degron in combination with a maltose-responsive promoter to control gene expression at the transcriptional level and to control protein stability at the post-translational level. The present disclosure also relates to the use of a stabilization construct that couples expression of a cell-growth-affecting protein with the production of non-catabolic compounds. The present disclosure further relates to the use of a synthetic maltose-responsive promoter. The present disclosure further provides compositions and methods for using a maltose dependent degron, a maltose-responsive promoter, and a stabilization construct, either alone or in various combinations, for the production of non-catabolic compounds in genetically modified host cells.
Owner:AMYRIS INC +1

Application of miR-206-3p in regulation and control of skeletal muscle atrophy

The invention belongs to the technical field of biological medicines, and particularly relates to application of miR-206-3p in regulation and control of skeletal muscle atrophy, and the change condition of the miR-206-3p level is measured by constructing an in-vitro cancer cachexia myotubular atrophy model; it is verified that in-vitro addition of miR-206-3p mimics relieves in-vitro myotube atrophy induced by a cancer conditioned culture medium, inhibits expression of a myotube marker gene and inhibits proteolysis and metabolism pathways and cell apoptosis of myotubes, so that myotube atrophy induced by cancer cachexia is inhibited. The invention opens up a new thought for the research of cachexia pathogenesis, and also provides a potential new target for the research and development of cachexia treatment and / or cachexia prevention drugs.
Owner:CHINA AGRI UNIV

Fat-reducing nutritional composition containing kelp extract and preparation method of fat-reducing nutritional composition

The invention provides a fat-reducing nutritional composition containing a kelp extract and a preparation method of the fat-reducing nutritional composition, belongs to the technical field of foods, and relates to fermentation engineering and marine food manufacturing. The fat-reducing nutritional composition comprises the following components: a kelp extract, opuntia ficus-indica powder, an enhancer, a flavoring agent and a nutritional agent, wherein the enhancer is prepared from calcium beta-hydroxy-beta-methyl butyrate, catechin and betaine. The fat-reducing nutritional composition disclosed by the invention is scientific in compatibility of the components, can effectively regulate catabolism of fat, improve fat consumption, reduce fat accumulation, timely supplement nutrition, prevent muscle loss, synchronously improve the metabolic level and immunity of a body, and achieve the effects of health and fat reduction.
Owner:FUJIAN RED SUN BOUTIQUE CO LTD

Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Tumor-selective expression of therapeutic molecules by bacteria is achieved by one or more AND, NOR, OR, NOT and / or NAND gate genetic circuits. The therapeutic molecules can be proteins, metabolites or catabolites, and may also be immunotherapeutics or immunotherapeutic cytotoxins. Single or multiple expression components may be used. Tumor selective expression of multimeric proteins utilizes multimerization as to complete the genetic circuit. Genetic circuits that are unlinked, function to achieve a combined effect on specificity of delivery of antitumor therapeutic molecules. Compositions and methods to generate silica, PEG and Poly-HPMA coated bacteria are also provided. Compositions and methods for selectively sensing or imaging tumors are also described.
Owner:BERMUDES DAVID GORDON

Catabolic nanocompartments

A method of breaking down at least one component of a substrate can include providing a catabolic nanocompartment that includes a liquid coacervate phase, at least one catalyst within the coacervate phase, and an aqueous phase surrounding the coacervate phase. The method can include contacting the catabolic nanocompartment with the substrate including the at least one component such that the catalyst degrades the at least one component and forms degradation products of the at least one component.
Owner:UNM RAINFOREST INNOVATIONS +5

Application of chlorella in preparation of medicine for treating osteoarthritis

The invention discloses application of chlorella in preparation of a medicine for treating osteoarthritis, in-vivo experiments and in-vitro experiments prove that chlorella can maintain a chondrocyte metabolism steady state, inhibit expression of chondrocyte extracellular matrix catabolism-related genes and proteins, and inhibit osteoarthritis. The expression of genes and proteins related to chondrocyte extracellular matrix anabolism is promoted, and by injecting a chlorella solution into a knee joint cavity, the effects of relieving and improving OA pain are achieved; furthermore, polydopamine is used for modifying the chlorella to obtain the polydopamine-coated chlorella Ch (at) P with a photothermal effect, and the Ch (at) P not only maintains the biological activity of the chlorella, but also has the effect of delaying cartilage degeneration and OA process due to the photothermal effect under near infrared (NIR) irradiation.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Recombinant cinnamon streptomyces and application thereof in monensin production

The invention provides recombinant cinnamon streptomyces and application thereof in monensin production, and belongs to the technical field of microbial fermentation and antibiotic preparation. According to the recombinant cinnamon streptomyces provided by the invention, a ccr gene with a nucleotide sequence shown as SEQ ID NO.2 in the cinnamon streptomyces is knocked out, and an xylA gene with a nucleotide sequence shown as SEQ ID NO.1 is overexpressed. According to the recombinant cinnamon streptomyces provided by the invention, through overexpression of the xylA gene, the metabolic capability of the cinnamon streptomyces to xylose is enhanced; the ccr gene is knocked out, so that the carbon catabolism inhibition phenomenon is weakened, and the xylose utilization rate is increased when the recombinant strain takes xylose as a carbon source. The recombinant streptomyces cinnamomi provided by the invention can improve the titer of monensin, reduce the production cost, shorten the fermentation period and improve the production efficiency.
Owner:JIANGNAN UNIV +1

Use of polypeptide in preparation of drugs, foods, or health care products for treating obesity and comorbidities thereof

Disclosed is use of a polypeptide in the preparation of drugs, foods, or health care products for treating obesity and comorbidities thereof, which belongs to the technical field of biological medicines. The polypeptide is a human GPR15L polypeptide or a mouse GPR15L polypeptide and a polypeptide conjugate thereof. The treatment of obesity includes: reducing fat accumulation, promoting fat thermogenesis and catabolism, increasing energy consumption, and reducing body weight. The obesity comorbidities include: chronic inflammation, fatty liver, steatohepatitis, metabolic diseases, cardiovascular and cerebrovascular diseases, osteoarticular diseases, Alzheimer's disease, depression, tumors, and skin diseases. A novel mechanism of action reduces blood glucose and body weight, thereby effectively treating obesity and comorbidities thereof.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV

Engineered auxin degrading microbiota for plant growth promotion

The present disclosure provides an engineered nucleic acid sequence comprising a gene cassette, the gene cassette comprising one or more regulator genes, the regulator genes including an iadR gene, and at least three catabolic pathway genes downstream from the one or more regulator genes, the at least three catabolic pathway genes including an iadC gene, an iadD gene, and an iadE gene, wherein the engineered nucleic acid sequence is free of an iadA gene and iadB gene. The disclosure also provides bacteria cells comprising the engineered nucleic acid sequence, wherein the bacteria cell is capable of degrading indole-3-acetic acid. Methods for degrading auxin, controlling auxin, and promoting plant growth and root development are provided, comprising providing the bacteria cell and allowing the bacteria cell to interact with roots of a plant.
Owner:THE TRUSTEES OF PRINCETON UNIV

A kitten food without palatability enhancers and its preparation method

This invention discloses a kitten food without palatability enhancers and its preparation method, relating to the field of pet food technology. It comprises the following components: polypeptide chicken meal, soy protein peptides, gluten hydrolysate, lactoferrin, astragalus extract, yam powder, rosemary oil, resveratrol, tributyrate, and rice. By adding substances containing small peptides and plant extracts to the kitten food, this invention provides the body with a large amount of high-quality animal protein without adding any chemically synthesized palatability enhancers, preservatives, or other chemical additives. This effectively promotes the body's decomposition and metabolism of nutrients, promotes the growth of kittens, and also enhances the body's antioxidant capacity and reduces the occurrence of diarrhea.
Owner:GRAD (FUJIAN) BIOTECHNOLOGY CO LTD

Hemp peptide nutritional fat-reducing yoghurt and preparation method thereof

The invention provides China-hemp peptide nutritional fat-reducing yoghourt and a preparation method thereof. Comprising the following raw materials in parts by weight: 85-92 parts of a fermented milk substrate, 1.2-1.8 parts of China-hemp protein, 0.02-0.05 part of a probiotic starter, 0.8-1.2 parts of China-hemp seeds and 4-6 parts of China-hemp seed oil microcapsule powder. The China-hemp peptide is combined with the yoghourt, so that the fat-reducing effect is remarkably improved while the taste of the product is ensured. Small-molecule active peptide obtained after extraction and hydrolysis of China-hemp protein can effectively inhibit lipase activity and promote catabolism of fat, and the function of regulating lipid metabolism is further enhanced through the synergistic effect of the small-molecule active peptide and probiotic strains. Through compounding use of the hemp seeds and the hemp protein, the stability problem of hemp peptide in an acid environment is solved, and the common defect of thin texture of traditional fat-reducing yoghurt is avoided. The prepared China-hemp peptide nutritional fat-reducing yoghurt is fine and full in texture, the biological activity of China-hemp peptide is fully reserved, the flavor is coordinated and natural, and the product has a definite fat-reducing function and also keeps the eating experience of traditional yoghurt.
Owner:天之草健康科技(长沙)有限公司

Fusarium graminearum pathogenicity inhibition method based on carbon metabolism regulation and application of fusarium graminearum pathogenicity inhibition method

The invention discloses a fusarium graminearum pathogenicity inhibition method based on carbon metabolism regulation and application of the fusarium graminearum pathogenicity inhibition method, and belongs to the field of agricultural disease control. The invention finds that the strain Pseudomonas sp.CXZ8 can influence the infection adaptability of fusarium graminearum through a targeted carbon catabolism repression pathway, that is, the strain Pseudomonas sp.CXZ8 can inhibit the expression of a fucosidase gene Fco1, interfere the nutrition utilization of pathogenic bacteria and prevent the pathogenic bacteria from infecting crops. Field and greenhouse inoculation tests prove that the disease index of the wheat scab can be remarkably reduced by spraying a fungicide prepared from the strain. Compared with traditional biological prevention and control, the invention provides a biological prevention and control strategy with carbon metabolism regulation as a target spot. The strategy provides possibility for accurately intervening the environmental adaptability of pathogenic bacteria and realizing prevention and control from the source, and also provides theoretical basis and technical support for green prevention and control work of wheat scab.
Owner:NORTHWEST A & F UNIV

Application of Phillyrin in the Preparation of Drugs for Treating Intervertebral Disc Degeneration

The present invention discloses the application of forsythin in the preparation of a medicament for treating intervertebral disc degeneration, belonging to the field of medical technology. In the study of intervertebral disc degeneration, it is found that forsythin can significantly inhibit the increase in catabolism and the decrease in anabolism of nucleus pulposus cells during the progression of intervertebral disc degeneration, and also has a significant inhibitory effect on the activation of the NF-κB pathway and the increase in ROS, thereby regulating the synthesis and catabolism of the extracellular matrix and cell apoptosis. Moreover, through verification, it is found that it has a therapeutic effect in a rat model of intervertebral disc degeneration, confirming that it also has a rescue effect on intervertebral disc degeneration in vivo.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Application of pentenedioic acid in enhancing anti-tumor effect of T cells through metabolic reprogramming

The invention provides application of pentenedioic acid (GC) in enhancing the anti-tumor effect of T cells through metabolic reprogramming, and belongs to the technical field of biological medicine. It is found that in the tumor development process, GC is supplemented in an exogenous mode, tumor growth can be rapidly inhibited, and the anti-tumor effect depends on a TME regulation and control mechanism. Through GC treatment, the TME immune landscape can be significantly remodeled; gC treatment not only can enhance the effector function of the CD8 + T cells, but also can delay the depletion process of the CD8 + T cells; and the infiltration CD8 + T cells in the tumor of the GC treatment group are obviously increased. Particularly, after the CD8-resistant antibody is used for removing mouse CD8 + T cells, the anti-tumor effect of GC completely disappears, and it is confirmed that the tumor inhibition effect depends on the CD8 + T cells. Therefore, the invention proves that the lysine catabolic metabolite GC, as an immunostimulatory metabolite, can shape the immune activated TME by reactivating the functions of tumor infiltrating CD8 + T cells.
Owner:ZHEJIANG UNIV

System for valve-based wastewater treatment control through microorganism metabolic pathway optimization

Increased control and efficiency over the wastewater purification can be achieved by allowing to selectively prioritize catabolic over anabolic processes via prioritization of the digestive function of microorganism in the activated sludge. The gas-dispersion return sludge is created using pure oxygen or oxygen containing trace amounts of ozone, which is blended with return sludge to create a mixture of gas and liquid, which is passed through an atomizer or a pump to instantly render the reactive gas to an ultra-fine bubble state. At least a portion of the ultra-fine bubbles dissolve within the sludge, raising oxygen to a critical level within a short time, activating the dormant microorganisms. The microorganisms accumulate enough cATP upon initial encounter with the pollutants to prioritize their digestive function, and when exposed to pollutants present in wastewater, digest the pollutants using biochemical pathways different from the ones used in nature.
Owner:OHKI AKIYOSHI +1

Methods and compositions useful for genetically modifying plant cells

The present invention provides for a library of binary vectors comprising a first library of first binary vectors, and a second library of second binary vectors, which in combination comprise genes of interests of a biosynthetic pathway or a catabolic pathway. The present invention provides for a method for introducing the genes of interest encoding for the enzymes of a biosynthetic pathway or a catabolic pathway into a target host cell comprising: (a) providing a library of host cells, (b) contacting the library of host cells to a target host cell resulting in introducing the genes of interest into the target host cell, and (c) identifying one or more the target host cell that are capable of synthesizing or catabolizing the compound of interest.
Owner:RGT UNIV OF CALIFORNIA